期刊文献+

普拉克索对脑梗死后帕金森病的临床疗效及安全性分析 预览

Clinical efficacy and safety of pramipexole in patients with Parkinson's disease after cerebral infarction
在线阅读 下载PDF
收藏 分享 导出
摘要 目的观察普拉克索对脑梗死后帕金森病的临床治疗效果及不良反应。方法将2016年2月~2018年6月期间我院治疗的86例脑梗死后帕金森患者随机分为对照组和观察组,各43例,两组患者均予改善循环、抗凝等基础治疗,对照组在基础治疗上予左旋多巴治疗,观察组患者在基础治疗上加用普拉克索治疗,两组治疗均为8周,比较两组患者临床疗效、治疗前后UPDRSⅡ、Ⅲ评分结果、血清C-反应蛋白(CRP)、白细胞介素-6(IL-6)等炎性因子水平及用药期间不良反应等。结果观察组患者临床总有效率明显高于对照组,差异均有统计学意义(P<0.05);两组患者治疗后UPDRSⅡ、Ⅲ评分均显著降低(P<0.05),经治疗后观察组患者UPDRSⅡ、Ⅲ评分显著低于对照组,差异有统计学意义(P<0.05);两组患者治疗后血清CRP、IL-6水平均下降,两组患者治疗后血清CRP、IL-6水平差异无统计学意义(P>0.05);对照组患者用药期间不良反应发生率(11.63%)与观察组(13.95%)相比,差异无统计学意义。结论普拉克索治疗脑梗死后帕金森患者疗效显著,可降低患者血清炎症水平,提高患者日常生活能力及运动能力,安全性高,适合临床推广。 Objective To observe the clinical effect and adverse reactions of pramipexole in patients with Parkinson's disease after cerebral infarction. Methods 86 patients with Parkinson's disease after cerebral infarction treated in our hospital from February 2016 to June 2018 were randomly divided into control group and observation group, with 43 cases in each group. Both groups were treated with basic therapy such as improvement of circulation and anticoagulation. The control group was treated with levodopa on the basis of basic treatment. The patients in the observation group were treated with pramipexole on the basis of basic treatment. Both groups were treated for 8 weeks. The clinical efficacy of the two groups, UPDRSⅡ,Ⅲ scores before and after treatment, serum C-reactive protein(CRP), interleukin-6 (IL-6) and other inflammatory factors and adverse reactions during the treatment were compared. Results The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05). The UPDRS Ⅱ and Ⅲ scores of the two groups were significantly lower after treatment(P<0.05). After treatment, the UPDRS Ⅱ and Ⅲ scores of the observation group were significantly lower than those of the control group(P<0.05). The serum CRP and IL-6 levels decreased after treatment in the two groups, and there was no significant difference between two groups(P>0.05). The incidence of adverse reactions during the treatment was not significantly different between the control group(11.63%) and the observation group(13.95%). Conclusion Pramexole treatment of Parkinson's disease after cerebral infarction is effective, which can reduce the level of serum inflammatory factors and improve patients' daily living ability and exercise capacity with high safety, thus it is suitable for clinical promotion.
作者 于莹 张娴 YU Ying;ZHANG Xian(Department of Pharmacy,Jiamusi Central Hospital,Jiamusi 154000,China;Department of Pharmacy,Chengdu First People's Hospital,Chengdu 610000,China)
出处 《中国现代医生》 2019年第11期126-128,132共4页
关键词 普拉克索 帕金森 脑梗死 安全性 Pramipex Parkinson's Cerebral infarction Safety
  • 相关文献

参考文献17

二级参考文献192

共引文献190

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏